1-4 of 4
peginesatide
Close
Sort by
Journal Articles

Comparison of Safety Reports to the FDA from a Pilot Introduction of Peginesatide, a Third Generation Erythropoiesis Stimulating Agent Versus Those from the Usual Care Setting: Manufacturers of Biosimilars and the FDA Should Consider Pilot Introductions of These Agents

Charles L. Bennett, MD PhD, Sony Jacob, MD, Peter Georgantopoulos, MPH, MA, Judy Nichols, MSN, ACNP, Iain C Macdougall, MD
Journal: Blood
Blood (2014) 124 (21): 3516.
https://doi.org/10.1182/blood.V124.21.3516.3516
Published: 2014
Journal Articles

Poor ESA Responders As Defined By Week 4 Hemoglobin Response Have Greater ESA Dosing but Worse Cardiovascular Outcomes in Patients with Anemia of Chronic Kidney Disease (CKD) Not on Dialysis

Robert C. Kane, MD, Qing Xu, PhD, Rajeshwari Sridhara, PhD, Justin Earp, PhD
Journal: Blood
Blood (2014) 124 (21): 4016.
https://doi.org/10.1182/blood.V124.21.4016.4016
Published: 2014
Journal Articles

Fatal and Serious Anaphylaxis Following Peginesatide Administration

Charles L. Bennett, MD, PhD, MPP, Sony Jacob, MD, Iain C Macdougall, MD, Tom Moore, Peter Georgantopoulos, MPH, MA, Judy Nichols, Paul Yarnold, PhD, Oliver Sartor, MD, Dennis W. Raisch, PhD, MS, RPh, Ashraf Mikhail, MD, LeAnn Norris, PharmD, Samuel Kessler, BA, Jametta Magwood, BA, David Goldsmith, MB, ChB
Journal: Blood
Blood (2013) 122 (21): 5612.
https://doi.org/10.1182/blood.V122.21.5612.5612
Published: 2013
Journal Articles

The Erythropoiesis Stimulating Agent Omontys/Peginesatide up-Modulates Erythroid Progenitor Formation, and Cell Surface Erythropoietin Receptor Levels.

Rakesh Verma, Ph.D, Jennifer M Green, PhD, Karen Leu, Richard B Mortensen, Peter R. Young, Peter J Schatz, Don M. Wojchowski, PhD
Journal: Blood
Blood (2012) 120 (21): 2089.
https://doi.org/10.1182/blood.V120.21.2089.2089
Published: 2012